Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC

NCT02959359 is registered in ClinicalTrials.gov with Taipei Veterans General Hospital, Taiwan as lead sponsor.

NCT NCT02959359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC
Lead sponsor
Taipei Veterans General Hospital, Taiwan
Phase
Phase 4
Overall status
Withdrawn
Start date
November 30, 2016
Completion date
December 31, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma